Form 4: Amicus Therapeutics CEO Bradley Campbell Executes Stock Options and Sells Shares

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,500 shares of common stock at a price of $8.61 per share.
• Simultaneously, Campbell sold 7,500 shares of common stock at a weighted average price of $11.6661, with individual prices ranging from $11.53 to $11.76.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.
• Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock and 60,000 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned and executed under a Rule 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry, to ensure compliance with insider trading regulations and to provide transparency to investors.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives.
• The use of Rule 10b5-1 trading plans is a standard practice to allow insiders to sell shares without concerns about insider trading, similar to practices at companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical.
• The size of the transaction is relatively small compared to the overall market capitalization of Amicus Therapeutics.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.
• The transactions are unlikely to significantly affect employees, customers, suppliers, or creditors.

Key Dates